Researchers from the U.S have now developed a new vaccine, believed to fight against glioblastoma multiforme or GBM, a form of brain tumor. The vaccine is hoped to fight brain tumor by delaying its progression.
Scientists say the vaccine increased survival rates by at least 18 months for the 23 patients of glioblastoma multiforme that it was tested on, reported the online edition of BBC News.
Advertisement
One in four brain tumours are glioblastoma multiforme (GBM), the most aggressive form of the primary brain tumours known collectively as gliomas.
These tumours arise from the supporting glial cells of the brain. These growths do not spread throughout the body like other forms of cancer, but cause symptoms by invading the brain.
The developed vaccine, an easy-to-use 'off-the-shelf' treatment, could potentially help half of all patients with glioblastoma multiforme (GBM), said Amy Heimberger, assistant professor of neurosurgery at the MD Anderson Cancer Center, Texas.
Trial results showed that the vaccine significantly delays the progression of tumours until the cancer finds a new way to grow. A larger trial of the vaccine, which works by targeting a protein thought to drive the tumour's spread, is now planned.
Edited IANS
Advertisement
The developed vaccine, an easy-to-use 'off-the-shelf' treatment, could potentially help half of all patients with glioblastoma multiforme (GBM), said Amy Heimberger, assistant professor of neurosurgery at the MD Anderson Cancer Center, Texas.
Trial results showed that the vaccine significantly delays the progression of tumours until the cancer finds a new way to grow. A larger trial of the vaccine, which works by targeting a protein thought to drive the tumour's spread, is now planned.
Edited IANS
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Mental Health News
Schizophrenic patients have a genetic link to increased cardiovascular risk factors, especially smoking and body mass index.
Mental health issues such as anxiety and depression could be precursors to multiple sclerosis (MS), even before the classic MS symptoms appear.
Studying brain circuits tied to PTSD's progression from acute to chronic states is vital for grasping its pathophysiology and crafting targeted treatments.
Older adults with COPD were roughly twice as likely to develop depression if they faced functional limitations.
In most scenarios, depression screening tools demonstrated superior performance compared to suicide risk screenings.
